Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 26

1.

Correction: First-in-human phase 1 study of the BTK inhibitor GDC-0853 in relapsed or refractory B-cell NHL and CLL.

Byrd JC, Smith S, Wagner-Johnston N, Sharman J, Chen AI, Advani R, Augustson B, Marlton P, Commerford SR, Okrah K, Liu L, Murray E, Penuel E, Ward AF, Flinn IW.

Oncotarget. 2019 Jun 4;10(38):3827-3830. doi: 10.18632/oncotarget.27011. eCollection 2019 Jun 4.

2.

Polatuzumab vedotin in combination with immunochemotherapy in patients with previously untreated diffuse large B-cell lymphoma: an open-label, non-randomised, phase 1b-2 study.

Tilly H, Morschhauser F, Bartlett NL, Mehta A, Salles G, Haioun C, Munoz J, Chen AI, Kolibaba K, Lu D, Yan M, Penuel E, Hirata J, Lee C, Sharman JP.

Lancet Oncol. 2019 Jul;20(7):998-1010. doi: 10.1016/S1470-2045(19)30091-9. Epub 2019 May 14.

PMID:
31101489
3.

A Clinically Applicable Gene-Expression Classifier Reveals Intrinsic and Extrinsic Contributions to Consensus Molecular Subtypes in Primary and Metastatic Colon Cancer.

Piskol R, Huw L, Sergin I, Kljin C, Modrusan Z, Kim D, Kljavin N, Tam R, Patel R, Burton J, Penuel E, Qu X, Koeppen H, Sumiyoshi T, de Sauvage F, Lackner MR, de Sousa E Melo F, Kabbarah O.

Clin Cancer Res. 2019 Jul 15;25(14):4431-4442. doi: 10.1158/1078-0432.CCR-18-3032. Epub 2019 Apr 19.

PMID:
31004000
4.

Polatuzumab vedotin or pinatuzumab vedotin plus rituximab in patients with relapsed or refractory non-Hodgkin lymphoma: final results from a phase 2 randomised study (ROMULUS).

Morschhauser F, Flinn IW, Advani R, Sehn LH, Diefenbach C, Kolibaba K, Press OW, Salles G, Tilly H, Chen AI, Assouline S, Cheson BD, Dreyling M, Hagenbeek A, Zinzani PL, Jones S, Cheng J, Lu D, Penuel E, Hirata J, Wenger M, Chu YW, Sharman J.

Lancet Haematol. 2019 May;6(5):e254-e265. doi: 10.1016/S2352-3026(19)30026-2. Epub 2019 Mar 29.

PMID:
30935953
5.

First-in-human phase 1 study of the BTK inhibitor GDC-0853 in relapsed or refractory B-cell NHL and CLL.

Byrd JC, Smith S, Wagner-Johnston N, Sharman J, Chen AI, Advani R, Augustson B, Marlton P, Renee Commerford S, Okrah K, Liu L, Murray E, Penuel E, Ward AF, Flinn IW.

Oncotarget. 2018 Jan 22;9(16):13023-13035. doi: 10.18632/oncotarget.24310. eCollection 2018 Feb 27. Erratum in: Oncotarget. 2019 Jun 04;10(38):3827-3830.

6.

Phase II Study of the Dual EGFR/HER3 Inhibitor Duligotuzumab (MEHD7945A) versus Cetuximab in Combination with FOLFIRI in Second-Line RAS Wild-Type Metastatic Colorectal Cancer.

Hill AG, Findlay MP, Burge ME, Jackson C, Alfonso PG, Samuel L, Ganju V, Karthaus M, Amatu A, Jeffery M, Bartolomeo MD, Bridgewater J, Coveler AL, Hidalgo M, Kapp AV, Sufan RI, McCall BB, Hanley WD, Penuel EM, Pirzkall A, Tabernero J.

Clin Cancer Res. 2018 May 15;24(10):2276-2284. doi: 10.1158/1078-0432.CCR-17-0646. Epub 2018 Mar 5.

7.

Randomized Phase II Study of Duligotuzumab (MEHD7945A) vs. Cetuximab in Squamous Cell Carcinoma of the Head and Neck (MEHGAN Study).

Fayette J, Wirth L, Oprean C, Udrea A, Jimeno A, Rischin D, Nutting C, Harari PM, Csoszi T, Cernea D, O'Brien P, Hanley WD, Kapp AV, Anderson M, Penuel E, McCall B, Pirzkall A, Vermorken JB.

Front Oncol. 2016 Oct 31;6:232. eCollection 2016.

8.

Battling Btk Mutants With Noncovalent Inhibitors That Overcome Cys481 and Thr474 Mutations.

Johnson AR, Kohli PB, Katewa A, Gogol E, Belmont LD, Choy R, Penuel E, Burton L, Eigenbrot C, Yu C, Ortwine DF, Bowman K, Franke Y, Tam C, Estevez A, Mortara K, Wu J, Li H, Lin M, Bergeron P, Crawford JJ, Young WB.

ACS Chem Biol. 2016 Oct 21;11(10):2897-2907. Epub 2016 Sep 7.

PMID:
27571029
9.

Phase Ib study of duligotuzumab (MEHD7945A) plus cisplatin/5-fluorouracil or carboplatin/paclitaxel for first-line treatment of recurrent/metastatic squamous cell carcinoma of the head and neck.

Jimeno A, Machiels JP, Wirth L, Specenier P, Seiwert TY, Mardjuadi F, Wang X, Kapp AV, Royer-Joo S, Penuel E, McCall B, Pirzkall A, Clement PM.

Cancer. 2016 Dec 15;122(24):3803-3811. doi: 10.1002/cncr.30256. Epub 2016 Aug 15.

10.

Integrated genomic analysis of colorectal cancer progression reveals activation of EGFR through demethylation of the EREG promoter.

Qu X, Sandmann T, Frierson H Jr, Fu L, Fuentes E, Walter K, Okrah K, Rumpel C, Moskaluk C, Lu S, Wang Y, Bourgon R, Penuel E, Pirzkall A, Amler L, Lackner MR, Tabernero J, Hampton GM, Kabbarah O.

Oncogene. 2016 Dec 15;35(50):6403-6415. doi: 10.1038/onc.2016.170. Epub 2016 Jun 6.

11.

Safety and Pharmacokinetics/Pharmacodynamics of the First-in-Class Dual Action HER3/EGFR Antibody MEHD7945A in Locally Advanced or Metastatic Epithelial Tumors.

Juric D, Dienstmann R, Cervantes A, Hidalgo M, Messersmith W, Blumenschein GR Jr, Tabernero J, Roda D, Calles A, Jimeno A, Wang X, Bohórquez SS, Leddy C, Littman C, Kapp AV, Shames DS, Penuel E, Amler LC, Pirzkall A, Baselga J.

Clin Cancer Res. 2015 Jun 1;21(11):2462-70. doi: 10.1158/1078-0432.CCR-14-2412.

12.

MMP-1 and Pro-MMP-10 as potential urinary pharmacodynamic biomarkers of FGFR3-targeted therapy in patients with bladder cancer.

Du X, Lin BC, Wang QR, Li H, Ingalla E, Tien J, Rooney I, Ashkenazi A, Penuel E, Qing J.

Clin Cancer Res. 2014 Dec 15;20(24):6324-35. doi: 10.1158/1078-0432.CCR-13-3336. Epub 2014 Oct 17.

13.

Biomarker analyses from a placebo-controlled phase II study evaluating erlotinib±onartuzumab in advanced non-small cell lung cancer: MET expression levels are predictive of patient benefit.

Koeppen H, Yu W, Zha J, Pandita A, Penuel E, Rangell L, Raja R, Mohan S, Patel R, Desai R, Fu L, Do A, Parab V, Xia X, Januario T, Louie SG, Filvaroff E, Shames DS, Wistuba I, Lipkind M, Huang J, Lazarov M, Ramakrishnan V, Amler L, Phan SC, Patel P, Peterson A, Yauch RL.

Clin Cancer Res. 2014 Sep 1;20(17):4488-98. doi: 10.1158/1078-0432.CCR-13-1836. Epub 2014 Mar 31.

14.

HGF as a circulating biomarker of onartuzumab treatment in patients with advanced solid tumors.

Penuel E, Li C, Parab V, Burton L, Cowan KJ, Merchant M, Yauch RL, Patel P, Peterson A, Hampton GM, Lackner MR, Hegde PS.

Mol Cancer Ther. 2013 Jun;12(6):1122-30. doi: 10.1158/1535-7163.MCT-13-0015. Epub 2013 Mar 27.

15.

Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors.

Wilson TR, Fridlyand J, Yan Y, Penuel E, Burton L, Chan E, Peng J, Lin E, Wang Y, Sosman J, Ribas A, Li J, Moffat J, Sutherlin DP, Koeppen H, Merchant M, Neve R, Settleman J.

Nature. 2012 Jul 26;487(7408):505-9. doi: 10.1038/nature11249.

16.

Trastuzumab has preferential activity against breast cancers driven by HER2 homodimers.

Ghosh R, Narasanna A, Wang SE, Liu S, Chakrabarty A, Balko JM, González-Angulo AM, Mills GB, Penuel E, Winslow J, Sperinde J, Dua R, Pidaparthi S, Mukherjee A, Leitzel K, Kostler WJ, Lipton A, Bates M, Arteaga CL.

Cancer Res. 2011 Mar 1;71(5):1871-82. doi: 10.1158/0008-5472.CAN-10-1872. Epub 2011 Feb 15.

17.
18.

Quantitation of p95HER2 in paraffin sections by using a p95-specific antibody and correlation with outcome in a cohort of trastuzumab-treated breast cancer patients.

Sperinde J, Jin X, Banerjee J, Penuel E, Saha A, Diedrich G, Huang W, Leitzel K, Weidler J, Ali SM, Fuchs EM, Singer CF, Köstler WJ, Bates M, Parry G, Winslow J, Lipton A.

Clin Cancer Res. 2010 Aug 15;16(16):4226-35. doi: 10.1158/1078-0432.CCR-10-0410. Epub 2010 Jul 27.

19.

HER kinase axis receptor dimer partner switching occurs in response to EGFR tyrosine kinase inhibition despite failure to block cellular proliferation.

Jain A, Penuel E, Mink S, Schmidt J, Hodge A, Favero K, Tindell C, Agus DB.

Cancer Res. 2010 Mar 1;70(5):1989-99. doi: 10.1158/0008-5472.CAN-09-3326. Epub 2010 Feb 16.

20.

EGFR over-expression and activation in high HER2, ER negative breast cancer cell line induces trastuzumab resistance.

Dua R, Zhang J, Nhonthachit P, Penuel E, Petropoulos C, Parry G.

Breast Cancer Res Treat. 2010 Aug;122(3):685-97. doi: 10.1007/s10549-009-0592-x. Epub 2009 Oct 27.

PMID:
19859802
21.

A novel proximity assay for the detection of proteins and protein complexes: quantitation of HER1 and HER2 total protein expression and homodimerization in formalin-fixed, paraffin-embedded cell lines and breast cancer tissue.

Shi Y, Huang W, Tan Y, Jin X, Dua R, Penuel E, Mukherjee A, Sperinde J, Pannu H, Chenna A, DeFazio-Eli L, Pidaparthi S, Badal Y, Wallweber G, Chen L, Williams S, Tahir H, Larson J, Goodman L, Whitcomb J, Petropoulos C, Winslow J.

Diagn Mol Pathol. 2009 Mar;18(1):11-21. doi: 10.1097/PDM.0b013e31818cbdb2.

PMID:
19214113
22.

Identification of a region within the ErbB2/HER2 intracellular domain that is necessary for ligand-independent association.

Penuel E, Akita RW, Sliwkowski MX.

J Biol Chem. 2002 Aug 9;277(32):28468-73. Epub 2002 May 8.

23.

Structural requirements for ErbB2 transactivation.

Penuel E, Schaefer G, Akita RW, Sliwkowski MX.

Semin Oncol. 2001 Dec;28(6 Suppl 18):36-42. Review.

PMID:
11774204
24.

The biology of human epidermal growth factor receptor 2.

Sundaresan S, Penuel E, Sliwkowski MX.

Curr Oncol Rep. 1999 Sep;1(1):16-22. Review.

PMID:
11122793
25.

Transformation by v-Src: Ras-MAPK and PI3K-mTOR mediate parallel pathways.

Penuel E, Martin GS.

Mol Biol Cell. 1999 Jun;10(6):1693-703.

26.

Chinese hamster ovary cells contain transcriptionally active full-length type C proviruses.

Lie YS, Penuel EM, Low MA, Nguyen TP, Mangahas JO, Anderson KP, Petropoulos CJ.

J Virol. 1994 Dec;68(12):7840-9.

Supplemental Content

Loading ...
Support Center